At the recent ASCO conference, the largest gathering of oncology professionals globally, the audience erupted in applause, with doctors expressing their excitement through cheers and whistles—a rare moment during a scientific presentation. Oncologist Brian Wolpin humorously noted from the stage that such a reaction was not planned in his speech. This enthusiastic response was in reaction to the trial results for daraxonrasib, a medication developed by Revolution Medicines. The drug was evaluated in a study involving 500 patients suffering from metastatic pancreatic cancer, whose conditions had worsened despite receiving first-line chemotherapy. The findings revealed that the median overall survival for patients taking daraxonrasib reached 13.2 months, in stark contrast to just 6.7 months for those undergoing standard chemotherapy. Additionally, the risk of mortality was reduced by 60%, and tumors either shrank or vanished in 31.6% of the participants. This innovative treatment is administered as a daily pill.
Daraxonrasib is categorized as a new type of RAS(ON) inhibitor, designed to target RAS/KRAS mutations—key contributors to tumor development. These mutations are found in a majority of pancreatic cancer cases but were previously deemed nearly impossible to target due to their complexity. However, daraxonrasib is capable of addressing a wide spectrum of these mutations simultaneously.
Moreover, the medication is reported to be more tolerable compared to traditional chemotherapy, with only 1.2% of patients discontinuing treatment due to adverse effects, compared to 11.2% in the chemotherapy group. The next step for daraxonrasib is to secure regulatory approval, with the FDA having already provided expanded access and committed to a faster review process.
Informational material. 18+.
